<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291407</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-012</org_study_id>
    <nct_id>NCT01291407</nct_id>
  </id_info>
  <brief_title>A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer</brief_title>
  <official_title>A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine maximum tolerated dose (MTD), dose limiting
      toxicities (DLT) and recommend a proper dose for our phase II study of S-1 when combined with
      radiation therapy for locally advanced or recurrent gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I trial of S-1 given in treatment days with an oral dose from 30mg/m2/d to
      80mg/m2/d, concurrently with radiation in patients with locally advanced or locally recurrent
      gastric cancer. Patients will be treated with external beam radiation therapy in a standard
      manner. S-1 will be administered for 6 dose levels,30/40/50/60/70/80mg/m2/d. Patients will be
      assessed for acute toxicities according to Common Toxicity Criteria for Adverse Effects
      (CTCAE)3.0.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define dose limited toxicities(DLT) of S-1, peroral BID, in treatment days concurrently with radiation therapy (RT) in locally advanced or recurrent gastric cancer.</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Dose limited toxicities defined as below: leucopenia ≥4 neutropenia ≥ 4, anemia ≥ 3, thrombocytopenia ≥ 3, alanine aminotransferase/aspartate aminotransferase (AST) ≥ 3, alkaline phosphatase (ALT) ≥ 3, total bilirubin ≥ 3,blood urea nitrogen (BUN)/Cr ≥ 2,non-granular cell decreased fever ≥ 2, nausea/vomiting ≥ 2, fatigue ≥ 3, weight loss ≥ 3, diarrhea ≥ 3, abdominal pain ≥ 3, dysphagia ≥ 3, hand-foot syndrome ≥ 2, neurotoxicity ≥ 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To define maximum tolerated dose(MTD) of S-1, peroral BID, in treatment days concurrently with radiation therapy</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>If 1 of 3 patients treated within a S-1 dose level experiences DLTs, 3 more patients will be treated at the same level. If a second patient experiences DLTs, then escalation will be stopped and the MTD is defined as the level below DLT dose level.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1,peroral BID,capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.</description>
    <arm_group_label>S-1,peroral BID,capsule</arm_group_label>
    <other_name>an oral fluorinated pyrimidine combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.</description>
    <arm_group_label>S-1,peroral BID,capsule</arm_group_label>
    <other_name>an oral fluorinated pyrimidine combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner</description>
    <arm_group_label>S-1,peroral BID,capsule</arm_group_label>
    <other_name>an oral fluorinated pyrimidine combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.</description>
    <arm_group_label>S-1,peroral BID,capsule</arm_group_label>
    <other_name>an oral fluorinated pyrimidine combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.</description>
    <arm_group_label>S-1,peroral BID,capsule</arm_group_label>
    <other_name>an oral fluorinated pyrimidine combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.</description>
    <arm_group_label>S-1,peroral BID,capsule</arm_group_label>
    <other_name>an oral fluorinated pyrimidine combination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven locally advanced gastric adenocarcinoma in
             patients undergoing R0, R1, R2 resection, or with unresectable or locoregional
             recurrent disease

          -  Any prior chemotherapy is allowed in this protocol.

          -  No distant metastasis in liver,lung,,bone,central nervous system(CNS),no peritoneal
             transplantation

          -  No prior abdominal or pelvic radiotherapy.

          -  Karnofsky performance status(KPS)≥ 70,predictive life span no less than 6 months

          -  Patients must have normal organ and marrow function as defined below:

               -  Leukocytes greater than or equal to 3,000 G/L

               -  Platelets: greater than or equal to 100,000/mm3

               -  Hemoglobin:greater than or equal to 10g/L

               -  Total bilirubin: within normal institutional limits

               -  AST/ALT: less than or equal to 1.5 times the upper limit

               -  Creatinine within normal upper limits

               -  Informed consent

          -  Without any serious complications,such as hypertension,coronary artery
             disease,psychiatric history.

        Exclusion Criteria:

          -  Patients with other cancer history except cervical carcinoma in situ and non-malignant
             melanoma skin cancer

          -  With any distant metastasis in liver,lung,,bone,CNS,or peritoneal transplantation

          -  History of allergic reactions attributed to similar chemical or biologic complex to
             S-1

          -  Uncontrolled illness including, but not limited to, active infection, symptomatic
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

          -  History of myocardial infarction within the past 6 months or history of ventricular
             arrhythmia

          -  History of prior radiation to the abdomen

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Jin, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology,Cancer Hospital and Institute,CAMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yexiong Li, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology,Cancer Hospital and Institute, CAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1.</citation>
    <PMID>10200776</PMID>
  </reference>
  <reference>
    <citation>Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I. [Phase I study of S-1. S-1 Study Group]. Gan To Kagaku Ryoho. 1997 Dec;24(15):2253-64. Japanese.</citation>
    <PMID>9422070</PMID>
  </reference>
  <reference>
    <citation>van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol. 2000 Jul;18(14):2772-9.</citation>
    <PMID>10894878</PMID>
  </reference>
  <reference>
    <citation>Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res. 2002 Jul;8(7):2116-22.</citation>
    <PMID>12114411</PMID>
  </reference>
  <reference>
    <citation>Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res. 2004 Aug 1;10(15):4913-21.</citation>
    <PMID>15297391</PMID>
  </reference>
  <reference>
    <citation>Takahashi I, Kakeji Y, Emi Y, Sakurai M, Yonemura Y, Kimura Y, Maehara Y. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer. 2003;6 Suppl 1:28-33.</citation>
    <PMID>12775017</PMID>
  </reference>
  <reference>
    <citation>Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998 Oct;34(11):1715-20.</citation>
    <PMID>9893658</PMID>
  </reference>
  <reference>
    <citation>Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 1999 Oct;57(3):202-10.</citation>
    <PMID>10545788</PMID>
  </reference>
  <reference>
    <citation>Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000 Apr;58(3):191-7.</citation>
    <PMID>10765119</PMID>
  </reference>
  <reference>
    <citation>Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.</citation>
    <PMID>17978289</PMID>
  </reference>
  <reference>
    <citation>Fujitani K, Tsujinaka T, Yamasaki H, Hirao M, Yoshida K, Kurokawa Y. Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy. Anticancer Res. 2009 Aug;29(8):3385-91.</citation>
    <PMID>19661361</PMID>
  </reference>
  <reference>
    <citation>Saikawa Y, Kubota T, Kumagai K, Nakamura R, Kumai K, Shigematsu N, Kubo A, Kitajima M, Kitagawa Y. Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):173-9. Epub 2007 Nov 8.</citation>
    <PMID>17996385</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Combined Modality</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>S-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 8, 2014</submitted>
    <returned>December 15, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

